Literature DB >> 21674557

Tumor-secreted lysophostatidic acid accelerates hepatocellular carcinoma progression by promoting differentiation of peritumoral fibroblasts in myofibroblasts.

Antonio Mazzocca1, Francesco Dituri, Luigi Lupo, Michele Quaranta, Salvatore Antonaci, Gianluigi Giannelli.   

Abstract

UNLABELLED: Hepatocellular carcinoma (HCC) occurs in fibrotic liver as a consequence of underlying cirrhosis. The goal of this study was to investigate how the interaction between HCC cells and stromal fibroblasts affects tumor progression. We isolated and characterized carcinoma-associated fibroblasts (CAFs) and paired peritumoral tissue fibroblasts (PTFs) from 10 different patients with HCC and performed coculture experiments. We demonstrated a paracrine mechanism whereby HCC cells secrete lysophostatidic acid (LPA), which promotes transdifferentiation of PTFs to a CAF-like myofibroblastic phenotype. This effect is mediated by up-regulation of specific genes related to a myo/contractile phenotype. After transdifferentiation, PTFs expressed α-smooth muscle actin (α-SMA) and enhanced proliferation, migration, and invasion of HCC cells occur. A pan-LPA inhibitor (α-bromomethylene phosphonate [BrP]-LPA), or autotaxin gene silencing, inhibited this PTF transdifferentiation and the consequent enhanced proliferation, migration, and invasion of HCC cells. In vivo, PTFs coinjected with HCC cells underwent transdifferentiation and promoted tumor progression. Treatment with BrP-LPA blocked transdifferentiation of PTFs, down-regulated myofibroblast-related genes, and slowed HCC growth and progression. Patients with larger and metastatic HCC and shorter survival displayed higher serum levels of LPA. Analysis of microdissected tissues indicated that stroma is the main target of the LPA paracrine loop in HCC. As a consequence, α-SMA-positive cells were more widespread in tumoral compared with paired peritumoral stroma.
CONCLUSION: Our data indicate that LPA accelerates HCC progression by recruiting PTFs and promoting their transdifferentiation into myofibroblasts. Inhibition of LPA could prove effective in blocking transdifferentiation of myofibroblasts and tumor progression.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21674557     DOI: 10.1002/hep.24485

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  54 in total

1.  Gα12 gep oncogene deregulation of p53-responsive microRNAs promotes epithelial-mesenchymal transition of hepatocellular carcinoma.

Authors:  Y M Yang; W H Lee; C G Lee; J An; E-S Kim; S H Kim; S-K Lee; C H Lee; D N Dhanasekaran; A Moon; S Hwang; S J Lee; J-W Park; K M Kim; S G Kim
Journal:  Oncogene       Date:  2014-07-28       Impact factor: 9.867

2.  Studying primary tumor-associated fibroblast involvement in cancer metastasis in mice.

Authors:  Annique M M J Duyverman; Ernst J A Steller; Dai Fukumura; Rakesh K Jain; Dan G Duda
Journal:  Nat Protoc       Date:  2012-03-22       Impact factor: 13.491

Review 3.  Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression.

Authors:  Lorenzo Federico; Kang Jin Jeong; Christopher P Vellano; Gordon B Mills
Journal:  J Lipid Res       Date:  2015-05-14       Impact factor: 5.922

Review 4.  Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014.

Authors:  Natalie J Torok; Jonathan A Dranoff; Detlef Schuppan; Scott L Friedman
Journal:  Hepatology       Date:  2015-03-10       Impact factor: 17.425

Review 5.  Molecular and cellular mechanisms of liver fibrosis and its regression.

Authors:  Tatiana Kisseleva; David Brenner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-30       Impact factor: 46.802

6.  Metabolomic Analysis of Liver Tissues for Characterization of Hepatocellular Carcinoma.

Authors:  Alessia Ferrarini; Cristina Di Poto; Shisi He; Chao Tu; Rency S Varghese; Abdalla Kara Balla; Meth Jayatilake; Zhenzhi Li; Kian Ghaffari; Ziling Fan; Zaki A Sherif; Deepak Kumar; Alexander Kroemer; Mahlet G Tadesse; Habtom W Ressom
Journal:  J Proteome Res       Date:  2019-07-01       Impact factor: 4.466

Review 7.  Cancer-associated fibroblasts in hepatocellular carcinoma.

Authors:  Norio Kubo; Kenichiro Araki; Hiroyuki Kuwano; Ken Shirabe
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

8.  Inhibition of connective tissue growth factor suppresses hepatic stellate cell activation in vitro and prevents liver fibrosis in vivo.

Authors:  Chunqiu Hao; Yumei Xie; Meijuan Peng; Li Ma; Yun Zhou; Yan Zhang; Wenzhen Kang; Jiuping Wang; Xuefan Bai; Pingzhong Wang; Zhansheng Jia
Journal:  Clin Exp Med       Date:  2013-03-02       Impact factor: 3.984

Review 9.  New Developments on the Treatment of Liver Fibrosis.

Authors:  Yukinori Koyama; Jun Xu; Xiao Liu; David A Brenner
Journal:  Dig Dis       Date:  2016-06-22       Impact factor: 2.404

10.  Unveiling the role of tumor reactive stroma in cholangiocarcinoma: an opportunity for new therapeutic strategies.

Authors:  Massimiliano Cadamuro; Stuart Duncan Morton; Mario Strazzabosco; Luca Fabris
Journal:  Transl Gastrointest Cancer       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.